Incorporation of Privileged Structures into Bevirimat Can Improve Activity against Wild-Type and Bevirimat-Resistant HIV-1 by Zhao, Yu et al.
Incorporation of Privileged Structures into Bevirimat Can 
Improve Activity against Wild-Type and Bevirimat-Resistant 
HIV-1
Yu Zhao†, Qiong Gu†,‡, Susan L. Morris-Natschke†, Chin-Ho Chen§, and Kuo-Hsiung Lee†,∥,*
†Natural Products Research Laboratories, UNC Eshelman School of Pharmacy, University of 
North Carolina, Chapel Hill, North Carolina 27599-7568, United States
‡Research Center for Drug Discovery, School of Pharmaceutical Sciences, Sun Yat-sen 
University, Guangzhou 510006, People’s Republic of China
§Surgical Oncology Research Facility, Duke University Medical Center, Box 2926, Durham, North 
Carolina 27710, United States
∥Chinese Medicine Research and Development Center, China Medical University and Hospital, 
404 Taichung, Taiwan
Abstract
Two “privileged fragments”, caffeic acid and piperazine, were integrated into bevirimat producing 
new derivatives with improved activity against HIV-1/NL4-3 and NL4-3/V370A carrying the most 
prevalent bevirimat-resistant polymorphism. The activity of one of these, 18c, was increased by 3-
fold against NL4-3 and 51-fold against NL4-3/V370A. Moreover, 18c is a maturation inhibitor 
with improved metabolic stability. Our study suggested that integration of privileged motifs into 
promising natural product skeletons is an effective strategy for discovering potent derivatives.
Graphical Abstract
INTRODUCTION
Human immunodeficiency virus (HIV)-caused HIV infection and acquired 
immunodeficiency syndrome (AIDS) were first identified over 30 years ago.1 Global AIDS 
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statistics from 2016 estimate that 36.7 million people were living with HIV in 2015.2 
Among them, two million were newly infected with HIV and 1.1 million died from AIDS-
related illnesses. Although over 30 drugs targeted at different steps of the viral life have been 
approved or are in experimental stages for treatment of HIV,3 a cure for HIV infection has 
not yet been found. HIV therapy suffers from the rapid emergence of drug-resistant viral 
strains and detrimental side effects caused by long-term drug treatment.3 Therefore, the 
discovery of new innovative anti-HIV agents is a research priority.
Betulinic acid (BA, 1, Figure 1), a naturally occurring triterpene, represents a promising 
structure type for anti-HIV agents.4 Bevirimat (2, Figure 1), 3-O-(3′,3′-dimethylsuccinyl)-
betulinic acid, discovered by our group, is the first-in-class maturation inhibitor.5 Compound 
2 interferes with the processing of P25 (CA-SP1) to CA, leading to the accumulation of P25 
and producing immature HIV-1 particles.6 In 2009, 2 succeeded in phase I and IIa clinical 
trials, thus proving its clinical efficacy and safety.7–9 Subsequent studies found that its 
effectiveness was reduced in the treatment of 40–50% of patients who carried resistant 
viruses associated with naturally occurring polymorphisms in the SP1 region of HIV-1 
Gag.10 This finding presented a high hurdle, blocking further clinical trials of 2 to treat HIV 
infection.
In our prior studies, new bevirimat derivative 3, with an amide bond between the C-28 
carboxylic acid of 2 and the secondary amine of 5-(piperazin-1-yl)pentanoic acid, exhibited 
improved anti-HIV activity, 15-fold better than that of 2.11 However, like 2, compound 3 
was ineffective against 2-resistant (BVM-R) viruses. Subsequently, 4, with a methyl 
nonanoylglutaminated side chain at C-28, exhibited at least 20-fold greater potency than 2 
against the replication of NL4-3/V370A, the variant of NL4-3 that carries the most prevalent 
clinical BVM-R polymorphism.12 These results suggested that the substituent at C-28 may 
play an important role in the drug–target interactions and appropriate C-28 substitutions 
could enhance the antiviral potency, especially against BVM-R virus.
A privileged substructure, initially proposed by Evans and coworkers in 1988,13 is a single 
molecular framework that is able to provide high affinity ligands for more than one type of 
receptor. Privileged substructural motifs can be observed frequently in a wide variety of 
bioactive natural products and therapeutic agents. They are recognized as significant 
elements for bioactivity and thus potentially important in drug design and discovery. 
Nowadays, privileged substructures are frequently used as starting points for design and 
construction of combinatorial libraries,14 especially diversity-oriented synthesis (DOS) 
libraries with high biological relevancy.15
Caffeic acid (3,4-dihydroxycinnamic acid, 5, Figure 2), found abundantly in many plants 
and foods, exhibits a broad spectrum of biological activities, including antioxidant, 
antimicrobial, and antiviral effects.16 Several caffeic acid related compounds are reported to 
exhibit anti-HIV activity as a single molecule or as a substructure (Figure 2).17 6′,6″-
Dinitrorosmarinic acid (6) with two caffeic acid motifs in the structure was reported to 
possess potent HIV-1 integrase inhibition and moderate anti-HIV activity in MT-4 cells.18 
(+)-Lithospermic acid (7), isolated from Salvia miltiorrhiza, is a caffeic acid trimer. It 
displayed HIV-1 integrase inhibitory activity at the submicromolar range and suppressed the 
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acute HIV-1 replication of H9 cells with IC50 at 2.0 µM.17 3,5-Dicaffeoylquinic acid (8), 
containing two caffeic acid motifs, was found to be active against HIV-1 integrase and HIV 
replication in MT-2 cell with IC50 at 1.9 µM.17 L-Chicoric acid (9), a major constituent of 
Echinacea purpurea roots and aerial parts, has been reported to show moderate inhibitory 
effect against HIV-1 integrase and HIV replication in MT-2 cells with IC50 at 4.2 µM.17 
Curcumin (10), a well-known natural product found in turmeric, contains two caffeic acid 
motifs and possesses diverse pharmacologic effects, including antitumor, anti-inflammatory, 
antioxidant, and antiviral properties. Extensive research has indicated that 10, a functionally 
labile molecule, can interact directly with several signal molecules, including HIV-1 
integrase and HIV protease.19,20 More recently, we have isolated two new enantiomeric 
carolignans, (+)-erythro-7′-methylcarolignan E (11a) and (−)-erythro-7′-methylcarolignan 
E (11b), from Euphorbia sikkimensis. These two compounds exhibited moderate anti-HIV 
activity with IC50 of 6.3 and 5.3 µM in MT-4 cells, respectively.21 Therefore, we envisioned 
that caffeic acid is a privileged structure that could be used in the design of new anti-HIV 
agents.
Piperazine is a well-known privileged structure. It is often found in many drugs, including 
anti-HIV drugs.22 Several studies have indicated that piperazine can contribute to improve 
druglike properties, such as bioavailability and metabolism.23,24 Moreover, from a chemical 
viewpoint, the two nitrogen atoms at opposite positions in the six-membered piperazine ring 
make this compound an ideal linker to connect desired motifs.
Pharmacophore merging is a useful strategy that has been applied widely in drug design and 
discovery. Merging different pharmacophores, which might have different mechanisms of 
action and targets, into one molecule may lead to a new agent with enhanced efficacy and 
the ability to conquer resistance to the parent drug.25 In the present study, we proposed to 
incorporate the aforementioned two privileged fragments, caffeic acid and piperazine, into 
the structure of 2 to design new derivatives with improved activity against wild and BVM-R 
virus (Figure 3).
As shown in Figure 3, first, since the 3-O-3′,3′-dimethylsuccinyl (C-3 dimethylsuccinyl 
ester) motif is the crucial antimaturation pharmacophore for 2,26 we retained this moiety. 
Second, due to its important role in the antiviral activity, the C-28 carboxylic acid of 2 was 
then chosen as the only position for connection of the privileged structures. Therefore, 
following this strategy, 18a, 18c, and 19 were synthesized. Moreover, incorporation of the 
two privileged structures into 3, rather than 2, was also performed to produce 23.
As we expected, the target compounds 18a, 18c, 19, and 23 exhibited improved activity 
against NL4-3 and NL4-3/V370A. Moreover, while the activity improved, the cytotoxicity 
did not obviously increase among these new compounds. Compound 18c was found to be 3-
fold more potent than 2 against wild-type NL4-3 virus and more importantly 51-fold more 
potent than 2 against NL4-3/V370A. A preliminary mechanism of action study indicated 
that 18c is a maturation inhibitor. Moreover, 18c was further found to show good metabolic 
stability. Herein, we report the design, synthesis, anti-HIV activity, preliminary mechanism 
of action study, and druglike properties of the new class of 2 derivatives.
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CHEMISTRY
The synthetic steps to produce 14c, 18a–c, 19, and 20 are shown in Scheme 1. 3,4-
Dimethoxycinnamic acid, 3,4-dimethoxymethylcinnamic acid, and 3,4-(methylenedioxy)-
cinnamic acid (12a–c) were purchased directly or synthesized according to reported 
methods.27 Acylation of 12a–c with 1-Boc-piperazine yielded 13a–c, respectively. The Boc 
protective group of 13a and 13c was removed easily with TFA in DCM. With 13b, ZnBr2, a 
mild Lewis acid, was used to remove the Boc group without affecting the MOM group also 
present on the phenyl ring. Subsequently, the deprotected 13a–c were then coupled to the 
C-28 carboxylic acid of betulinic acid 3-O-acetate (3-OAc-BA, 15) following the reported 
method,28 giving 16a–c, respectively. Hydrolysis of the 3-OAc of 16a–c with 4 N NaOH 
produced 17a–c, which were then esterified with 2,2-dimethylsuccinic anhydride to yield 
target compounds 18a–c. Furthermore, the MOM group in 18b was removed with 4 N HCl 
in EtOAc to produce 19. Acylation of 15 with 1-Boc-piperazine followed by esterification 
with 2,2-dimethylsuccinic anhydride gave 20.
Synthesis of 23 containing a long chain at C-28 was achieved by the methods shown in 
Scheme 2. Compound 21, prepared via the reported methods,11 was coupled with the 
deprotected 13c and then further converted to the target compound 23 by the esterification 
reactions described above.
RESULTS AND DISCUSSION
Compounds 5, 12c, 14c, 17a–c, 18a–c, 19, 20, 22, and 23, in parallel with 2, were first 
evaluated for their anti-HIV-1 replication activity against wild-type HIV-1/NL4-3. As shown 
in Table 1, all compounds containing 2 or 3 linked with piperazine and caffeic acid related 
structures exhibited potent activity with IC50 ranging from 0.012 to 0.05 µM. The order of 
potency was 23 > 18c > 19 ≥ 18a > 18b. The potencies of the target compounds 18a, 18c, 
19, and 23 were significantly improved by 2.2- to 5.4-fold, as compared to that of 2 (Table 1, 
Supporting Information Table S1 and Figure S1).
Meanwhile, the precursor compounds [(3-OH-28-modified derivatives (17a–c, 22)] without 
a C-3 dimethylsuccinyl ester were uniformly ineffective with IC50 greater than 1 µM (data 
not shown). These results indicated that combining a caffeic acid related moiety with 1, 
which does not have the antimaturation pharmacophore, is not enough to generate anti-HIV 
activity. Connecting piperazine to the C-28 position of 2 produced 20, which is a 
substructure (precursor) of the caffeic acid containing derivatives 18a–c, 19, and 23. 
However, 20 (IC50, 0.49 µM) was 8-fold less active than 2 (IC50, 0.065 µM). These results 
suggested that in addition to piperazine, a caffeic acid related fragment is required for the 
improved anti-HIV activity of this compound type. However, on the other hand, caffeic acid 
(5) and 3,4-(methylenedioxy)cinnamic acid (12c) showed no selectivity or no activity as 
single compounds against the NL4-3 virus. Connecting 12c to piperazine produced the 
inactive 14c, which is a substructure of 18c.
Although 5 does contain a catechol, which is identified as a pan-assay interference 
compound (PAIN),29 5 itself and 12c, 14c, 17a–c, and 22 containing a caffeic acid related 
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moiety exhibited no selectivity (for 5) or no activity against NL4-3 with IC50 > 1 µM. On the 
other hand, compounds with a caffeic acid related structure and piperazine incorporated into 
the skeleton of 2, including 18a–c, 19, and 23, all exhibited significant potency (IC50 from 
0.012 to 0.050 µM). These results clearly indicated that caffeic acid and its related structures 
function as privileged structures but not PAINS in the present study. Moreover, as 
exemplified in Figure 4, although the independent privileged structures showed no respective 
activity, properly morphing them onto the triterpene skeleton dramatically led to significant 
anti-HIV potency.
Subsequently, 18a, 18c, 19, and 23 were further evaluated against NL4-3/V370A. As we 
speculated, all four tested compounds exhibited improved activity against V370A by 1.39-
fold to 51.40-fold in comparison to 2. The order of potency was 18c > 19 > 18a > 23 (Table 
1 and Figure S1). This trend was almost the same as that against NL4-3 virus except for 23, 
which was the most potent compound against the NL4-3 virus but the least potent against 
the V370A virus. The structure of 23 is similar to that of the most potent 18c except for a 
piperazinepentanoic acid group in 23 between the C-28 carbonyl and the piperazine 
connected to the caffeic acid motif. This result suggested that, different from the wild-type 
virus, the long piperazinepentanoic acid motif at C-28 is not favorable for optimal activity 
against the BVM-R virus.
Except for 23, compounds 18a, 18c, and 19 exhibited more improved activity (greater fold-
change compared with 2) against the NL4-3/V370A virus than NL4-3 virus. Compound 18c 
was the most potent compound against NL4-3/V370A with an IC50 of 0.15 µM. Compared 
with 2, the potency of 18c was increased by 3-fold against wild-type and 51-fold against the 
BVM-resistant virus. Moreover, the improved antiviral activity did not accompany 
cytotoxicity, as evidenced from CC50 of more than 4.5 µM against MT-4 cells with all tested 
compounds, including 2.
Although the actual potency of 18c against the BVM-resistant virus did decrease by 7.9-
fold, compared to potency against wild-type virus (0.15 µM versus 0.019 µM), this decrease 
was much less than the 119-fold reduction in potency exhibited by 2 (7.71 µM versus 0.065 
µM) and 18-fold reduction in potency of 4, the best compound discovered before.12 Thus, 
18c, the best new compound in this privileged structure triterpene type, holds promise for 
further development of derivatives to entirely overcome resistance to 2.
Mechanism Study
NL4-3 and NL4-3/V370A differ only in the identity of the amino acid at the Gag 370 
position: Val in NL4-3 compared with Ala in V370A.12 However, this minor difference led 
to a 7.9-fold and 119-fold reduction in potency of 18c and 2, respectively, which strongly 
suggested that, like 2, 18c is a Gag maturation inhibitor. In contrast, caffeic acid related 
molecules are most often reported to target the HIV integrase.17–19 Moreover, some C-28 
modified BA derivatives were reported to block HIV-1 replication at the viral entry step.26,30 
Therefore, we wanted to determine whether 18c, which contains a caffeic acid related 
moiety as a privileged structure at C-28, inhibits HIV-1 entry or integrase. First, 18c was 
tested in a fusion assay, which can sensitively detect inhibition of HIV entry. The entry 
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inhibitor A43D, a BA derivative with a C-28 modified side chain,30 was used as a control. 
As shown in Figure 5A, our fusion assay indicated that A43D strongly inhibited entry 
NL4-3 Env-mediated cell–cell fusion, while 18c and 2 showed no activity. These results 
indicated that 18c does not inhibit HIV-1 entry. Second, 18c, 2, and A43D were further 
screened in a TZM-bl assay, which can detect anti-HIV-1 agents targeting HIV at a step prior 
to the full expression of HIV-1 tat, required to trigger the expression of luciferase under the 
control of HIV-1 promotor, LTR. However, this assay is unable to detect HIV-1 maturation 
inhibitors, which block HIV-1 replication only at a later step of the viral life cycle.11 As 
shown in Figure 5B, our TZM-bl assay indicated that A43D at 2 µM totally inhibited the 
NL4-3 infection of TZM-bl cells. In contrast, 18c and 2 at the same concentration exhibited 
no inhibition. Altogether, our results suggest that 18c with two privileged structures, a 
caffeic acid related portion and piperizine, at C-28 is primarily a maturation inhibitor.
In Vitro Metabolic Stability and in Silico Druglike Profiles
To evaluate its potential as a drug candidate, 18c in parallel with 2 was further investigated 
for in vitro metabolic stability with propranolol as reference. As shown in Table S2, 18c 
exhibited stable microsomal stability (t1/2 = 128 min) and low clearance [CLint = 0.054 (mL/
min)/mg]. In the same assay conditions, the in vitro half-life of 2 was 54 min. These results 
indicated that 18c’s metabolic stability is even better than that of 2, which was reported to 
show a long elimination half-life (t1/2 of 56.3–69.5 h) in healthy volunteers.8 In addition, the 
solubility, PSA (polar surface area) [a prediction of oral bioavailability],31 and 
hepatotoxicity of 18c were calculated using the ADMET module of Discovery Studio 2.5. 
The results predicted slightly increased solubility for 18c as compared with 2, although 
neither was optimally soluble. Moreover, 18c’s PSA and hepatotoxicity values indicated that 
our modification at the C-28 position of 2 did not decrease the bioavailability or induce liver 
toxicity (Table S2).
CONCLUSION
Since the discovery of 2 as the first-in-class HIV-1 maturation inhibitor, extensive 
modifications have been conducted on 2, such as various changes at the C-3-OH, C-28 
carboxylic acid, and C-30 allylic position or alterations of the skeleton, including replacing 
the C–O bonds at C-28 by C–C bonds. Hundreds of derivatives were thus 
produced.11,12,26,28,30,32–34 Among them, 4 was found to be over 20-fold more potent than 2 
against the BVM-R virus. However, the improved activity of 4 was achieved by connecting a 
rather bulky group, methyl nonanoyl-glutaminate, to the C-28 of 2. In other reported studies, 
the C-28 carboxylic acid was converted to an alkylamine to produce a new series of 
derivatives with potent anti-HIV maturation activity.32 The activity of the most potent 
compound against the BVM-R virus, reported therein, was improved by over 50-fold. 
However, its cytotoxicity (CC50 = 0.425 µM) against MT-4 cells also increased.
In our present study, we successfully identified a new type of derivative of 2 through 
integration of two privileged structures into 2, without alteration of the skeleton of 2. The 
activities of the compounds designed were improved against the wild virus and the BVM-
resistant virus, without increasing cytotoxicity. New compound 18c was identified as a lead 
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compound. Compared with 2, compound 18c was 3-fold more potent against NL4-3 and 51-
fold more potent against NL4-3/V370A. Moreover, 18c is primarily a maturation inhibitor 
with increased metabolic stability. Therefore, 18c merits further development as a promising 
anti-HIV clinical trial candidate. Further optimization and mechanism of action studies on 
18c are ongoing in our laboratory, and the results will be reported in due course.
It is well acknowledged that natural products are one of the most important and valuable 
resources in novel drug discovery. Numerous successful studies have indicated that 
appropriate chemical manipulation of functional groups on a natural product can lead to 
significant improvement in drug profiles. In the present study, privileged structures were 
successfully introduced into our modification of 2 for a new derivative type with an 
improved drug profile. We believe that such strategy may be generally useful or, at least, 
shed light on other natural-product-based drug discovery.
EXPERIMENTAL SECTION
Chemistry
All reagents and solvents were used as received from Sigma-Aldrich or other commercial 
source.1H NMR spectra were measured on an Inova 400 MHz spectrometer with Me4Si 
(TMS) as internal standard. High resolution mass spectra were produced on a Shimadzu 
LCMS-IT-TOF with ESI interface. HPLC purity determinations were conducted using a 
Shimadzu LCMS-2010 with Shimadzu SPD-M20A detector at 205 or 220 nm wavelength 
and a Grace Alltima 2.1 mm × 150 mm HP C18 5 µm column. A linear gradient of 35% 
acetonitrile in water to 100% acetonitrile with a flow rate of 0.3 mL/min was used. All 
compounds were at least 95% pure. Thin-layer chromatography (TLC) was performed on 
Merck percolated silica gel 60 F-254 plates. To purify all synthetic compounds, silica gel 
chromatography was carried out on a ISCO CombiFlash Rf flash chromatograph system 
with prepacked Redi Sep Rf Si gel column (Teledyne ISCO).
General Procedures for Synthesis of 17a–c
To a solution of 16a–c (1 mmol) in MeOH (4 mL) and THF (8 mL) was added 4 N NaOH (4 
mL). The reaction was stirred overnight. The mixture was then neutralized with 1 N HCl and 
extracted three times with DCM. The combined organic layers were dried over Na2SO4 and 
concentrated under vacuum. The residue was chromatographed using a silica gel column to 
yield the pure compound.
General Procedures for the Synthesis of 18a–c and 23
An appropriate derivative of 1 (1 equiv), 2,2-dimethylsuccinic anhydride (5 equiv), and 
DMAP (1 equiv) were dissolved in anhydrous pyridine. The mixture was stirred at 155 °C 
for 2 h in a microwave oven (Biotage). The reaction mixture was diluted with EtOAc and 
neutralized with HCl (1 N) and then extracted twice with EtOAc. The combined organic 
layer was washed with brine, dried over Na2SO4, and concentrated in vacuum to afford the 
crude product, which was chromatographed using a silica gel column to give the pure 18a–c 
and 23.
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Compound 18a
40.4 mg (41%), starting from 82.5 mg of 17a; white amorphous powder. Mp 165–166 °C.1H 
NMR (400 MHz, CD3Cl3): δ 7.66 (1H, d, J = 15.2 Hz, CH=), 7.12 (1H, dd, J = 2.0, 8.4 Hz, 
6-Ph), 7.03 (1H, d, J = 2.0 Hz, 2-Ph), 6.87 (1H, d, J = 8.4 Hz, 5-Ph), 6.71 (1H, d, J = 15.2 
Hz, CH=), 4.73 and 4.70 (1H each, 2s, H-29), 4.49 (1H, dd, J = 6.8, 11.8 Hz, H-3), 3.93 and 
3.92 (3H each, s, 2 × OCH3), 3.67 (8H, brs, 28-CON(CH2CH2)2-N-), 2.98 (1H, m, H-19), 
2.67 and 2.57 (1H each, d, J = 16.0 Hz, H-2′), 1.69 (3H, s, H-30), 1.31 and 1.29 (3 H each, 
s, 2 × CH3-3′), 0.96 (3H, s, CH3), 0.93 (3H, s, CH3), 0.84 (3H, s, CH3), 0.83 (3H, s, CH3), 
0.81 (3H, s, CH3). HRMS (ESI, m/z) calcd for C51H73N2O8, 841.5367 [M – H+]; found, 
841.5422.
Compound 18b
82.3 mg (19%), starting from 350 mg of 17b; colorless oil.1H NMR (400 MHz, CD3Cl3): δ 
7.63 (1H, d, J = 15.2 Hz, CH=), 7.34 (1H, s, 2-Ph), 7.15 (2H, s, 5,6-Ph), 6.72 (1H, d, J = 
15.6 Hz, CH=), 5.27 and 5.26 (2H each, 2s, 2 × O–CH2–O), 4.73 and 4.59 (1H each, 2s, 
H-29), 4.49 (1H, dd, J = 5.6, 10.0 Hz, H-3), 3.67 (8H, brs, 28-CON(CH2CH2)2-N-), 3.54 
and 3.52 (3H each, 2s, 2 × OCH3), 2.98 (1H, m, H-19), 2.63 and 2.56 (1H each, d, J = 16.0 
Hz, H-2′), 1.69 (3H, s, H-30), 1.30 and 1.29 (3 H each, s, 2 × CH3-3′), 0.96 (3H, s, CH3), 
0.93 (3H, s, CH3), 0.84 (3H, s, CH3), 0.83 (3H, s, CH3), 0.80 (3H, s, CH3). HRMS (ESI, 
m/z) calcd for C53H79N2O10, 903.5734 [M + H+]; found, 903.5682.
Compound 18c
52.0 mg (52%), starting from 84.5 mg of 17c; white amorphous powder. Mp 179–180 °C.1H 
NMR (400 MHz, CDCl3): δ 7.62 (1H, d, J = 15.2 Hz, CH=), 7.04 (1H, s, 2-Ph), 7.01 (1H, d, 
J = 8.0 Hz, 6-Ph), 6.81 (1H, d, J = 8.0 Hz, 5-Ph), 6.69 (1H, d, J = 15.2 Hz, CH=), 6.00 (2H, 
s, O–CH2–O), 4.73 and 4.59 (1H each, 2s, H-29), 4.48 (1H, t, J = 7.6 Hz, H-3), 3.66 (8H, 
brs, 28-CON(CH2CH2)2-N-), 2.97 (1H, m, H-19), 2.67 and 2.56 (1H each, d, J = 15.6 Hz, 
H-2′), 1.69 (3H, s, H-30), 1.30 and 1.29 (3 H each, s, 2 × CH3-3′), 0.96 (3H, s, CH3), 0.93 
(3H, s, CH3), 0.83 (6H, s, CH3 × 2), 0.80 (3H, s, CH3). HRMS (ESI, m/z) calcd for 
C50H69N2O8, 825.5054 [M – H+]; found, 825.5059.
Compound 23
52.1 mg (41%), starting from 110.0 mg of 22; colorless oil.1H NMR (400 MHz, CDCl3): δ 
7.62 (1H, d, J = 15.2 Hz, CH=), 7.03 to 7.00 (2H, overlap, 2,6-Ph), 6.81 (1H, d, J = 8.0 Hz, 
5-Ph), 6.67 (1H, d, J = 15.2 Hz, CH=), 6.00 (2H, s, O–CH2–O), 4.72 and 4.57 (1H each, 2s, 
H-29), 4.47 (1H, t, J = 6.8 Hz, H-3), 3.71–3.50 (12 H, overlap, 28-CON(CH2CH2)2-N- and -
CON(CH2)2), 2.96 (1H, m, H-19), 2.53 to 2.35 (8H, overlap, -(CH2)2-N-, N-CH2 and H-2′), 
1.67 (3H, s, H-30), 1.25 (6H, s, 2 × CH3-3′), 0.93 (6H, s, 2 × CH3), 0.82 (3H, s, CH3), 0.80 
(6H, s, 2 × CH3). HRMS (ESI, m/z) calcd for C59H87N4O9, 995.6473 [M + H+]; found, 
995.6415.
Convert 18b to 19
To a solution of 18b (1 mmol) in DCM (5 mL) was added 4 N HCl in EtOAc (5.5 mL, 22 
mmol). The mixture was stirred for 4 h at rt. The solvent was then removed in vacuo. The 
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residue was purified by chromatography on a silica gel column to give the pure compound 
19 (39.7 mg, 60%); colorless oil.1H NMR (400 MHz, CD3OD): δ 7.48 (1H, d, J = 15.2 Hz, 
CH=), 7.06 (1H, s, 2-Ph), 6.99 (1H, dd, J = 2.0, 8.0 Hz, 6-Ph), 6.88 (1H, d, J = 15.6 Hz, 
CH=), 6.77 (2H, s, 5-Ph), 4.70 and 4.59 (1H each, 2s, H-29), 4.44 (1H, dd, J = 5.2, 10.8 Hz, 
H-3), 3.69 (8H, brs, 28-CON(CH2CH2)2-N-), 2.98 (1H, m, H-19), 2.61 and 2.54 (1H each, 
d, J = 16.4 Hz, H-2′), 1.70 (3H, s, H-30), 1.25 and 1.24 (3 H each, s, 2 × CH3-3′), 1.02 (3H, 
s, CH3), 0.96 (3H, s, CH3), 0.89 (3H, s, CH3), 0.85 (3H, s, CH3), 0.84 (3H, s, CH3). HRMS 
(ESI, m/z) calcd for C49H71N2O8, 815.5210 [M + H+]; found, 815.5159.
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ABBREVIATIONS USED
AIDS acquired immunodeficiency syndrome
BA betulinic acid
Boc N-tert-butoxycarbonyl
BVM-R bevirimat-resistant
DCM dichloromethane
DMAP 4-(dimethylamino)pyridine
DMF dimethylformamide
EDCI 1-ethyl - 3 - (3-dimethylaminopropyl)carbodiimide 
hydrochloride
Et3N triethylamine
EtOAc ethyl acetate
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Gag group-specific antigen
HIV-1 human immunodeficiency virus type 1
HLM human liver microsome
HOBt 1-hydroxybenzotriazole
MOMCl chloromethyl methyl ether
PAINS pan-assay interference compounds
P24 (CA) capsid
P25 (CA-SP1) capsid precursor
TBS tert-butyldimethylsilyl
TFA trifluoroacetic acid
THF tetrahydrofuran
TZM-bl JC53bl-13
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Figure 1. 
Structures of betulinic acid (1), bevirimat (2), and its analogues with improved anti-HIV 
activity against wild-type virus (3) or BVM-R virus (4).
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Figure 2. 
Caffeic acid related compounds exhibit potent anti-HIV activity as a single molecule or as a 
substructure.
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Figure 3. 
Incorporation of two privileged fragments into the structure of 2 to design new derivatives.
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Figure 4. 
Joining appropriate privileged structures to the triterpene skeleton can generate significant 
potency.
Zhao et al. Page 16
J Med Chem. Author manuscript; available in PMC 2017 October 13.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 5. 
(A) Compound 18c did not inhibit HIV-1 Env-mediated cell–cell fusion. Each data point in 
the figure represents the average of two independent tests. (B) Compound 18c showed no 
activity in NL4-3 infection of TZM-bl assays. NL4-3 infection of TZM-bl cells without 
compounds was used as control. % control infection is 100 × RLUcpd/RLUctr. RLUcpd and 
RLUctr are the relative luminescence units of the experimental infection and control 
infection, respectively. All compounds were tested at 2 µM. The numbers in the figure are 
derived from the average of two tests.
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Scheme 1. Synthesis of Compounds 14c, 18a– c, 19, and 20a
a(a) 1-Boc-piperazine, HOBt, EDCI, Et3N, DCM, overnight; (b) 13a,c TFA, DCM, 2 h; or 
13b ZnBr2, DCM, 24 h; (c) oxalyl chloride, DCM, then deprotected 13a–c (for 16a–c) or 1-
Boc-piperazine (for 20), Et3N, DCM, 6 h; (d) 4 N NaOH, THF/MeOH, overnight; (e) 2,2-
dimethylsuccinic anhydride, DMAP, pyridine, microwave 155 °C, 2 h; (f) 4 N HCl in 
EtOAc, DCM, 4 h.
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Scheme 2. Synthesis of Compound 23a
a(a) (i) 13c, TFA, CH2Cl2 2 h; (ii) HOBt, EDCI, Et3N, overnight.; (b) 2,2-dimethylsuccinic 
anhydride, DMAP, pyridine, microwave 155 °C, 2 h.
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Table 1
Antiviral and Cytotoxic Activity Data
IC50(μM)a
compd NL4-3 NL4-3/V370A RFCd
CC50 (µM), MT-4
cell
18a 0.029 ± 0.0093 2.97c 102.41 >4.5
18b 0.050 ± 0.021 >4.5
18c 0.019 ± 0.0054 0.15 ± 0.052 7.89 >4.5
19 0.028 ± 0.010 2.21c 78.93 >4.5
23 0.012 ± 0.0041 5.53c 460.83 >4.5
20 0.49 ± 0.12 >1.5
14c >90 >90
12c >90 >90
5 NSb
2 0.065 ± 0.019 7.71c 118.62 >4.5
a
Data are presented as the mean ± standard deviation (SD) and determined in three separate experiments. The P values derived from a two-sided 
Student t test between a compound and 2 are presented in Table S1.
bNS: no selective anti-HIV activity (CC50/IC50 < 5).
c
Data presented are averages of three separate experiments.
d
Resistance fold change (RFC) is the IC50(NL4-3/V370A)/IC50(NL4-3) ratio.
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